Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZSTARYS vs ADDERALL 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary p H >7.
AZSTARYS is a prodrug that is converted to dexmethylphenidate primarily through enzymatic hydrolysis by carboxylesterase 1 (CES1). The active metabolite dexmethylphenidate is further metabolized primarily via deesterification to ritalinic acid, with minor hydroxylation pathways.
Amphetamine is metabolized via CYP2D6, with deamination and oxidation as major pathways.
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
Serdexmethylphenidate: 94% (bound to albumin); dexmethylphenidate: 15-20%.
~16% bound to plasma proteins (primarily albumin).
Serdexmethylphenidate: 5.6 L/kg; dexmethylphenidate: 2.7 L/kg. High Vd indicates extensive tissue distribution.
3.5–4.5 L/kg; indicates extensive tissue distribution (e.g., brain, lungs).
Oral: 100% for serdexmethylphenidate (prodrug); dexmethylphenidate from the prodrug is 87% bioavailable relative to equivalent dexmethylphenidate dose.
Oral immediate-release: 96–100% (first-pass metabolism minimal); extended-release: approximately 96% relative to immediate-release.
e GFR 15-29 m L/min: not recommended; e GFR <15 m L/min: contraindicated. No dose adjustment for e GFR >=30 m L/min.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: use maximum of 50% of usual dose; not recommended in ESRD.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Age 6-12 years: initial 19.6 mg oral once daily; titrate weekly by 19.6 mg; max 78.4 mg. Age 13-17 years: same as adult dosing.
Children 3-5 years: initial 2.5 mg daily, increase by 2.5 mg weekly; max 40 mg/day. Children ≥6 years: initial 5 mg once or twice daily, increase by 5 mg weekly; max 40 mg/day (or 20 mg/day for extended-release).
No specific studies in elderly; initiate at low end of dosing range due to increased sensitivity to sympathomimetics. Monitor cardiovascular status.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg weekly; monitor for cardiovascular effects and confusion.
AZSTARYS has a high potential for abuse and misuse, which can lead to dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Adderall has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase: Monitor closely for tachycardia and hypertension.,Psychiatric adverse events: May precipitate psychotic or manic symptoms in patients with no prior history, or exacerbate symptoms in those with pre-existing psychiatric disorders.,Priapism: Prolonged and painful erections may occur, requiring immediate medical attention.,Peripheral vasculopathy: Including Raynaud's phenomenon, monitor for digital changes.,Long-term suppression of growth: Monitor growth in pediatric patients during treatment.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Blood pressure and heart rate increases,Psychiatric adverse events such as psychosis or mania,Growth suppression in pediatric patients,Seizures,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when co-administered with serotonergic drugs
Hypersensitivity to methylphenidate products or any component of AZSTARYS,Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Tics or family history of Tourette's syndrome,Severe anxiety, tension, or agitation
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Hypersensitivity to amphetamine products
High-fat meals delay time to peak concentration (Tmax) by approximately 2 hours but do not affect overall exposure (AUC). Avoid alcohol as it may alter drug release characteristics. No specific food restrictions; can be taken with or without food.
Avoid acidic foods or vitamin C supplements within 1 hour of dosing as they decrease absorption. Grapefruit may increase drug levels. Caffeine and other stimulants should be limited. Avoid alcohol. High-fat meals may delay onset but not overall absorption.
Pregnancy Category C. First trimester: Animal studies show increased risk of fetal malformations (e.g., cardiac, skeletal). Second/third trimester: Potential for preterm delivery, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) due to chronic exposure.
Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularly cardiovascular defects and oral clefts, but absolute risk is low. Second and third trimesters: Exposure may increase risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms including irritability, dysphoria, and feeding difficulties. Chronic use may lead to fetal growth restriction.
Excreted in human milk; M/P ratio not established. Limited data suggest potential for adverse effects in nursing infants (e.g., irritability, poor feeding). Decision to breastfeed should weigh risks and benefits; consider alternative feeding if drug is essential.
Amphetamine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2.0–3.0. Relative infant dose is estimated at 5–10% of the maternal weight-adjusted dose. Use while breastfeeding is generally not recommended due to potential adverse effects on the infant, including irritability, poor feeding, and insomnia. Consider alternative treatments or discontinue breastfeeding.
No established dose adjustments in pregnancy; however, increased clearance may reduce efficacy. Titrate to lowest effective dose. Consider alternative therapies if possible due to unknown risks.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) can lower amphetamine plasma concentrations. Dose adjustments may be necessary to maintain therapeutic effect; however, formal guidelines are lacking. Use the lowest effective dose and monitor clinical response. Avoid during pregnancy unless potential benefits outweigh risks.
AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is a prodrug combination with immediate-release and delayed-release components. Onset of action occurs within 1 hour, and duration is approximately 13 hours. It can be taken with or without food, but high-fat meals delay peak concentration. Avoid use in patients with pre-existing cardiovascular disease, hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Monitor for growth suppression in children, weight loss, and insomnia. Avoid concomitant use with MAOIs or within 14 days of discontinuation. May exacerbate tics or Tourette syndrome. Use with caution in patients with seizure disorder or those taking CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) due to increased dexmethylphenidate exposure.
ADDERALL 5 (amphetamine/dextroamphetamine) is a CNS stimulant. Note that 5 mg is a low starting dose; titrate based on response and tolerability. Avoid use in patients with structural cardiac abnormalities, glaucoma, hyperthyroidism, or history of drug abuse. Monitor for hypertension, tachycardia, and psychiatric symptoms. Can worsen tics or Tourette syndrome. Use with caution with MAOIs (risk of hypertensive crisis).
Take exactly as prescribed; do not crush or chew capsules.,Avoid alcohol while taking this medication.,Report any chest pain, shortness of breath, or palpitations immediately.,May cause dizziness or blurred vision; avoid driving until effects are known.,Use with caution in patients with history of drug dependence or abuse.,Keep out of reach of children; do not share medication.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose without consulting doctor.,Swallow tablet whole; do not crush or chew.,Avoid taking late in the day to prevent insomnia.,May cause dizziness; avoid driving if affected.,Report chest pain, shortness of breath, or fainting.,May be habit-forming; do not share with others.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZSTARYS vs ADDERALL 5, answered by our medical review team.
AZSTARYS is a CNS Stimulant that works by AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.. ADDERALL 5 is a CNS Stimulant that works by Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZSTARYS and ADDERALL 5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZSTARYS is: Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.. The standard adult dose of ADDERALL 5 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZSTARYS and ADDERALL 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZSTARYS is classified as Category C. Pregnancy Category C. First trimester: Animal studies show increased risk of fetal malformations (e.g., cardiac, skeletal). Second/third trimester: Potential for preterm delivery, . ADDERALL 5 is classified as Category C. Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.